Materials and methods for respiratory disease control in canines
Inventors
Crawford, Patti C. • Gibbs, Paul J. • Dubovi, Edward J. • Donis, Ruben Omar • Katz, Jacqueline • Klimov, Alexander I. • Lakshmanan, Nallakannu P. • Lum, Melissa Anne • Goovaerts, Daniel Ghislena Emiel • Mellencamp, Mark William • Cox, Nancy J. • Castleman, William L.
Assignees
Cornell Research Foundation Inc • Centers of Disease Control and Prevention CDC • University of Florida Research Foundation Inc • US Department of Health and Human Services
Publication Number
US-7959929-B2
Publication Date
2011-06-14
Expiration Date
2026-04-21
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The subject invention pertains to isolated influenza virus that is capable of infecting canids and causing respiratory disease in the canid. The subject invention also pertains to compositions and methods for inducing an immune response against an influenza virus of the present invention. The subject invention also pertains to compositions and methods for identifying a virus of the invention and diagnosing infection of an animal with a virus of the invention.
Core Innovation
The subject invention pertains to isolated influenza viruses capable of infecting canids and causing respiratory disease, including the identification of specific canine influenza viruses and genes encoding viral proteins such as hemagglutinin (HA). It provides compositions, such as vaccines comprising at least one equine influenza virus antigen, H3 influenza virus antigen, and/or H7 influenza virus antigen, and methods for inducing immune responses against these viruses in canines.
The invention addresses the need to control infectious tracheobronchitis (``kennel cough``), a prevalent respiratory infection in dogs causing coughing and other symptoms. Existing outbreaks in racing greyhounds showed severe illness and mortality, with the causative agents not fully elucidated. The invention provides tools to diagnose, prevent, and treat influenza virus infections in canines, including vaccine compositions, diagnostic methods, and therapeutic applications.
Furthermore, the invention describes methods for isolating the virus, identifying viral genes and proteins (notably HA with specific amino acid changes), producing recombinant constructs, and preparing vaccines, including inactivated and attenuated formulations. The vaccines can be administered via various routes to protect canines from infection, reduce viral shedding, and ameliorate symptoms. The invention also encompasses diagnostic kits and methods for detecting infection and viral nucleic acids to aid in disease control and surveillance.
Claims Coverage
The patent includes multiple inventive features focusing on isolated canine influenza viruses, vaccines, compositions, methods of inducing immune responses, recombinant constructs, and diagnostic tools.
Isolated canine influenza virus with specific HA polypeptide
An isolated canine influenza virus comprising a polynucleotide encoding a hemagglutinin polypeptide having the amino acid sequence of SEQ ID NO:33 or with 99% or greater sequence identity to SEQ ID NO:33, including viruses designated A/canine/Florida/43/2004 and related isolates.
Vaccines comprising inactivated or attenuated canine influenza virus
Vaccine compositions comprising inactivated or attenuated forms of the isolated canine influenza virus described, formulated with pharmaceutically acceptable carriers or diluents and optionally adjuvants, suitable for inducing protective immune responses in canines.
Methods for inducing immune responses against canine influenza
Methods for inducing an immune response in a canid animal by administering an effective amount of a vaccine or composition comprising the isolated canine influenza virus or viral polynucleotide encoding HA with specific amino acid features, to prevent or suppress influenza infection or symptoms.
Reassortant and recombinant viruses encoding canine influenza components
Reassortant viruses comprising one or more genes or polynucleotides encoding HA polypeptides of the canine influenza virus, including variants with key amino acid substitutions defining the canine-adapted strain.
Diagnostic compositions and kits for detecting canine influenza
Compositions and kits comprising antibodies, polynucleotides, or peptides specific to viral proteins (such as HA or NP) of the canine influenza virus for detecting infection or diagnosing disease in canines.
The claims protect isolated canine influenza viruses with defined HA sequences, vaccine formulations comprising these viruses, methods for immunization of canines, recombinant and reassortant viral constructs, and diagnostic tools, all aimed at controlling and detecting respiratory disease caused by canine influenza virus.
Stated Advantages
Provides vaccines capable of protecting canines from canine influenza infection and associated symptoms.
Enables diagnosis and identification of canine influenza virus infection in animals.
The vaccine compositions may reduce or prevent viral shedding, thereby limiting transmission.
Vaccination can reduce disease severity, incidence, and associated respiratory lesions in infected canines.
The invention includes compositions suitable for diverse canine populations, including domestic, wild, and working dogs.
Documented Applications
Vaccination of canines, including domestic dogs such as greyhounds, to prevent or reduce the risk of influenza virus infection and respiratory disease.
Diagnosis of canine influenza infection through detection of viral nucleic acids or antibodies in biological samples.
Use of vaccines, including inactivated and live attenuated forms, to induce protective immune responses in dogs.
Use of recombinant viral vectors or polypeptides corresponding to canine influenza virus antigens in vaccine compositions.
Use of canine influenza viruses and reassortants in challenge models for testing vaccine efficacy or antiviral agents.
Interested in licensing this patent?